🔗 Permalink

Inventor profile of:

Ming Yan

City:

Encino, California

Country:

United States

Published Applications:

Last publication date:

2025-06-12

Top Assignees for applications by Ming Yan

The entities that hold a legal rights for patent applications filed by inventor Yan Ming:

Rampart Bioscience, Inc. 4 Monrovia, CA United States
The Regents of the University of California 3 Oakland, CA United States
CSL Behring Gene Therapy, Inc. 3 Pasadena, CA United States
CSL Gene Therapy Pty Ltd. 2 Parkville, Australia
CSL Gene Therapy Pty Ltd. 1 Melbourne, Australia
Calimmune Inc. 1 Tucson, AZ United States
Calimmune Australia Pty Ltd 1 Darlinghurst, Australia

Recent patent applications by Yan Ming

Ming Yan from Encino, US has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-06-12

US20250188487A1

Chemistry; metallurgy

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS

#2 | 2025-06-05

US20250179517A1

Chemistry; metallurgy

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS

#3 | 2025-05-08

US20250146016A1

Chemistry; metallurgy

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS

#4 | 2025-05-08

US20250146015A1

Chemistry; metallurgy

NON-IMMUNOGENIC CIRCULAR, NON-VIRAL DNA VECTORS

#5 | 2024-05-09

US20240150737A1

Chemistry; metallurgy

SOLUBLE ALKALINE PHOSPHATASE CONSTRUCTS AND EXPRESSION VECTORS INCLUDING A POLYNUCLEOTIDE ENCODING FOR SOLUBLE ALKALINE PHOSPHATASE CONSTRUCTS

#6 | 2024-02-08

US20240043845A1

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES

#7 | 2022-03-10

US20220072046A1

Human necessities

MODULATABLE SWITCH FOR SELECTION OF DONOR MODIFIED CELLS

#8 | 2021-11-11

US20210348170A1

Chemistry; metallurgy

Compositions and methods for treating beta-hemoglobinopathies

#9 | 2021-11-04

US20210340563A1

Chemistry; metallurgy

DONOR T-CELLS WITH KILL SWITCH

#10 | 2021-10-21

US20210322331A1

Human necessities

NANOCAPSULES FOR THE DELIVERY OF CELL MODULATING AGENTS

#11 | 2021-10-14

US20210316013A1

Human necessities

HAEMATOPOIETIC STEM CELL-GENE THERAPY FOR WISKOTT-ALDRICH SYNDROME

#12 | 2020-12-24

US20200397712A1

Human necessities

NOVEL RNAi MOLECULE DELIVERY PLATFORM BASED ON SINGLE-siRNA AND shRNA NANOCAPSULES

#13 | 2020-02-06

US20200038444A1

Human necessities

Modulatable switch for selection of donor modified cells

#14 | 2019-08-22

US20190256855A9

Chemistry; metallurgy

COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES

#15 | 2019-04-04

US20190100759A1

Chemistry; metallurgy

Compositions and methods for treating beta-hemoglobinopathies

#16 | 2019-02-21

US20190054119A1

Human necessities

Modulatable switch for selection of donor modified cells

#17 | 2018-02-08

US20180036254A1

Human necessities

RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules

#18 | 2015-03-12

US20150071999A1

Human necessities

RNAi molecule delivery platform based on single-siRNA and shRNA nanocapsules

#19 | 2014-07-03

US20140186436A1

Human necessities

ORAL DELIVERY OF ENZYMES BY NANOCAPSULES FOR TARGETED METABOLISM OF ALCOHOL OR TOXIC METABOLITES

InventorID:

823554 ⎘